7699-35-6
中文名稱
(E)-3-(3H-咪唑-4-基)丙-2-烯酸
英文名稱
(E)-3-(3H-imidazol-4-yl)prop-2-enoic acid
CAS
7699-35-6
分子式
C6H6N2O2
分子量
138.12
MOL 文件
7699-35-6.mol
更新日期
2023/03/20 15:41:21
7699-35-6 結構式
基本信息
中文別名
順式-尿刊酸順-咪唑丙烯酸
順 - 尿刊酸
(E)-3-(3H-咪唑-4-基)丙-2-烯酸
英文別名
cis-UCANsc407934
(Z)-Urocanic acid
cis-Urocanic acid
Urocanic acid, cis
Cis-Urocanic Acid-[13C3]
(αZ)-1H-Imidazole-4-acrylic acid
(Z)-3-(1H-Imidazole-4-yl)acrylic acid
(Z)-3-(1H-Imidazol-4-yl)propenoic acid
(2Z)-3-(1H-Imidazole-4-yl)acrylic acid
常見問題列表
生物活性
cis-Urocanic acid 是一種 5-HT2A 受體激動劑。cis-Urocanic acid 以較高親和力與 5-HT 受體結合，Kd 為 4.6 nM。cis-Urocanic acid 是一種免疫調(diào)節(jié)劑，通過與 5-HT2A 受體結合而誘導免疫抑制。靶點
|
5-HT 2A Receptor
|
體外研究
Treatment with 100 μg/mL cis-Urocanic acid (cis-UCA) completely suppresses IL-6 and IL-8 secretion, decreases caspase-3 activity, and improves cell viability against UV-B irradiation. No significant effects on IL-6 or IL-8 secretion, caspase-3 activity, or viability of the non-irradiated cells are observed with 100 μg/mL cis-Urocanic acid in both cell types. The 5000 μg/mL concentration is toxic.
Cell Viability Assay
| Cell Line: | Human corneal epithelial cells (HCE-2) and human conjunctival epithelial cells (HCECs) |
| Concentration: | 10, 100, 1,000, and 5,000 μg/mL |
| Incubation Time: | 24, 48, or 72 hours |
| Result: | Treatment with 100 μg/mL completely suppressed IL-6 and IL-8 secretion, decreased caspase-3 activity, and improved cell viability against UV-B irradiation. No significant effects on IL-6 or IL-8 secretion, caspase-3 activity, or viability of the non-irradiated cells were observed with 100 μg/mL in both cell types. |